secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2026-05-12T20:07:01+00:00
Accession:  0001448431-26-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q1 rev $19.8M, adj EBITDA $3.3M; guides FY rev $95-100M, refi saves $1.5M
--------------------------------------------------------------------------------

- Q1 revenue $19.8M (down 10% YoY), GAAP net loss $(0.5)M ($(0.03)/share) vs $(2.2)M loss a year ago.
- Non-GAAP net income $2.7M ($0.14/diluted), adjusted EBITDA $3.3M vs $1.5M prior year.
- FY 2026 revenue guidance updated to $95-100M; adjusted EBITDA guidance unchanged $21-25M.
- Refinanced debt with Fifth Third Bank: $25M term loan + $10M revolver, annual interest savings ~$1.5M.
- Launched efficiency initiatives expected to save $3M annually, including $1M in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/0001448431-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000009/oprx-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001448431-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer